X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs AJANTA PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES AJANTA PHARMA VENUS REMEDIES/
AJANTA PHARMA
 
P/E (TTM) x -9.4 22.1 - View Chart
P/BV x 0.1 5.2 2.8% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 VENUS REMEDIES   AJANTA PHARMA
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-17
AJANTA PHARMA
Mar-18
VENUS REMEDIES/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs1431,818 7.9%   
Low Rs651,106 5.9%   
Sales per share (Unadj.) Rs324.2239.5 135.4%  
Earnings per share (Unadj.) Rs6.452.8 12.1%  
Cash flow per share (Unadj.) Rs40.659.5 68.2%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs366.0230.0 159.1%  
Shares outstanding (eoy) m12.3488.77 13.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.36.1 5.2%   
Avg P/E ratio x16.227.7 58.5%  
P/CF ratio (eoy) x2.624.6 10.4%  
Price / Book Value ratio x0.36.4 4.5%  
Dividend payout %00-   
Avg Mkt Cap Rs m1,282129,782 1.0%   
No. of employees `0000.96.8 13.3%   
Total wages/salary Rs m2513,765 6.7%   
Avg. sales/employee Rs Th4,430.13,128.4 141.6%   
Avg. wages/employee Rs Th278.0554.0 50.2%   
Avg. net profit/employee Rs Th87.6689.7 12.7%   
INCOME DATA
Net Sales Rs m4,00021,258 18.8%  
Other income Rs m23242 9.4%   
Total revenues Rs m4,02321,499 18.7%   
Gross profit Rs m7856,584 11.9%  
Depreciation Rs m422596 70.8%   
Interest Rs m3444 8,382.9%   
Profit before tax Rs m426,226 0.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-371,539 -2.4%   
Profit after tax Rs m794,686 1.7%  
Gross profit margin %19.631.0 63.3%  
Effective tax rate %-87.924.7 -355.5%   
Net profit margin %2.022.0 9.0%  
BALANCE SHEET DATA
Current assets Rs m2,60612,236 21.3%   
Current liabilities Rs m1,9803,461 57.2%   
Net working cap to sales %15.641.3 37.9%  
Current ratio x1.33.5 37.2%  
Inventory Days Days12860 213.1%  
Debtors Days Days4384 51.1%  
Net fixed assets Rs m5,35311,140 48.1%   
Share capital Rs m123177 69.8%   
"Free" reserves Rs m4,39320,237 21.7%   
Net worth Rs m4,51620,414 22.1%   
Long term debt Rs m1,61810 16,021.8%   
Total assets Rs m8,29124,486 33.9%  
Interest coverage x1.11,519.4 0.1%   
Debt to equity ratio x0.40 72,423.4%  
Sales to assets ratio x0.50.9 55.6%   
Return on assets %5.119.2 26.6%  
Return on equity %1.823.0 7.6%  
Return on capital %6.330.5 20.6%  
Exports to sales %00-   
Imports to sales %18.40-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m736NA-   
Fx inflow Rs m011,667 0.0%   
Fx outflow Rs m7361,616 45.6%   
Net fx Rs m-73610,052 -7.3%   
CASH FLOW
From Operations Rs m9972,854 34.9%  
From Investments Rs m-461-2,604 17.7%  
From Financial Activity Rs m-571-2 28,550.0%  
Net Cashflow Rs m-35248 -14.1%  

Share Holding

Indian Promoters % 32.9 73.8 44.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 1.6 11.6%  
FIIs % 0.6 7.6 7.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 17.0 390.6%  
Shareholders   20,121 20,968 96.0%  
Pledged promoter(s) holding % 36.4 4.4 828.2%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   ABBOTT INDIA  JUBILANT LIFE SCIENCES  BIOCON LTD  PIRAMAL ENTERPRISES  NATCO PHARMA  

Compare VENUS REMEDIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Nifty Crosses 11,500-Mark; L&T Surges 4% on Buyback News(09:30 am)

Asian stock markets are higher today as Japanese and Hong Kong shares show gains. The Nikkei 225 is up 0.2% while the Hang Seng is up 0.7%.

Related Views on News

AJANTA PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 11.6% (Quarterly Result Update)

Aug 1, 2018 | Updated on Aug 1, 2018

For the quarter ended June 2018, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 11.6% YoY). Sales on the other hand came in at Rs 5 bn (up 8.0% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 17.1% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, AJANTA PHARMA has posted a net profit of Rs 945 m (down 17.1% YoY). Sales on the other hand came in at Rs 5 bn (up 11.2% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Only on WhatsApp, a Weaker Rupee Means a Weaker India(Vivek Kaul's Diary)

Aug 16, 2018

While dollar crossing Rs 70 will have its repercussions, the world isn't exactly coming to an end.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Aug 20, 2018 10:45 AM

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES - CADILA HEALTHCARE COMPARISON

COMPARE VENUS REMEDIES WITH

MARKET STATS